What's New with Roche Pathology Lab

VENTANA PD-L1 (SP263) Assay is intended for the qualitative detection of the programmed death ligand 1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and other tumor tissues stained with OptiView DAB IHC Detection Kit on a BenchMark IHC/ISH instrument.

PATHWAY HER2/neu (4B5) Rabbit Monoclonal Primary Antibody is a pre-diluted reagent for use on the Roche BenchMark IHC/ISH automated slide staining instruments.

The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene status.

Cancer continues to be a significant societal challenge as the 2nd leading cause of death in the United States and worldwide.1 In the US, approximately 1.9 million new cancer cases were expected to be diagnosed in 2022.1 Of these cases, the vast majority will consist of solid tumors, approximately 14% of which will have been shown to have defects in any of the MMR proteins.

Roche today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying epithelial ovarian cancer (EOC) patients who are eligible for targeted treatment with ELAHERE™ (mirvetuximab soravtansine-gynx).

PRAME (PReferentially expressed Antigen in MElanoma) is a tumor biomarker expressed in most cutaneous and ocular melanomas.

We have been making advancements in HER2 testing, breast cancer research, and treatment since 1990. Discover our history, innovations, and current HER2 efforts.

The BenchMark ULTRA PLUS system uses an unprecedented, fully-automated workflow for immunohistochemistry (IHC) and in-situ hybridization (ISH) slide staining to decrease touchpoints.

Workflow flexibility meets high-capacity with the VENTANA DP 600 slide scanner featuring a slide tray-based system and built-in calibrations.